Starling Oncology, Inc. planned insider sales
In the last twelve months insiders at Starling Oncology, Inc. filed 6 Form 144 notices of planned sales, 504,808 shares worth $2.8 million at the time of filing, from 5 sellers. The latest, filed 21 August 2026: Bradford Hively (director), 298,853 shares worth $2.0 million, planned for around 21 August 2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
| Filed | Seller | Relationship | Shares | Value | Planned sale | Sold, per Form 4 | Broker | How acquired | Filing |
|---|---|---|---|---|---|---|---|---|---|
| 21 August 2026 | Bradford Hively | Director | 298,853 | $2.0 million | 21 August 2026 | 298,853 shares from 21 August 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Open Market Purchase; Restricted Stock Units | Form 144 |
| 14 July 2026 | Yale Podnos | Officer | 23,452 | $146,575 | 14 July 2026 | 23,452 shares from 14 July 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 8 June 2026 | Yale Podnos | Officer | 23,451 | $114,206 | 8 June 2026 | 23,451 shares from 8 June 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 14 April 2026 | Mohit Kaushal | Director | 95,719 | $315,873 | 14 April 2026 | 95,719 shares from 14 April 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Restricted Stock Units | Form 144 |
| 15 December 2025 | Bradford Daniel Hively | Director | 13,333 | $50,291 | 15 December 2025 | 13,333 shares from 15 December 2025 | Morgan Stanley Smith Barney LLC Executive Financial Services | Restricted Stock | Form 144 |
| 18 November 2025 | Mark Pacala | Director | 50,000 | $200,000 | 18 November 2025 | 50,000 shares from 18 November 2025 | Morgan Stanley Smith Barney LLC Executive Financial Services | Restricted Stock | Form 144 |
A Form 144 is the notice an insider files with the SEC before selling restricted or control shares over the Rule 144 thresholds; it says what may be sold, not what was.